Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHANGHAI STOCK EXCHANGE  >  Beijing Tongrentang Co., Ltd.    600085   CNE000000R69

BEIJING TONGRENTANG CO., LTD.

(600085)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
29.59(c) 29.87(c) 29.87(c) 29.48(c) 29.5 Last
4 061 441 3 159 842 3 301 062 2 923 226 2 169 474 Volume
-0.90% +0.95% 0.00% -1.31% +0.07% Change
More quotes
Financials (CNY)
Sales 2019 15 549 M
EBIT 2019 2 454 M
Net income 2019 1 201 M
Finance 2019 6 373 M
Yield 2019 1,12%
Sales 2020 16 949 M
EBIT 2020 2 655 M
Net income 2020 1 319 M
Finance 2020 7 290 M
Yield 2020 1,22%
P/E ratio 2019 33,61
P/E ratio 2020 30,53
EV / Sales2019 2,19x
EV / Sales2020 1,96x
Capitalization 40 458 M
More Financials
Company
BEIJING TONGRENTANG CO., LTD is a China-based company principally engaged in the production and sales of traditional Chinese patent medicines. The Company’s main products consist of liuwei dihuang series, tongren dahuoluo series, tongren niuhuang qingxin series, angong niuhuang series and... 
Sector
Pharmaceuticals
Calendar
06/11 | 09:00pmShareholder meeting
More about the company
Surperformance© ratings of Beijing Tongrentang Co., L
Trading Rating : Investor Rating :
More Ratings
Latest news on BEIJING TONGRENTANG CO., L
03/28As China pushes traditional medicine globally, illegal wildlife trade flouris..
RE
03/21BEIJING TONGRENTANG CO., LTD. : annual earnings release
2013CORRECTED-From street stalls to bourses, SE Asia's traditional medicine maker..
RE
More news
Analyst Recommendations on BEIJING TONGRENTANG CO., L
More recommendations
Sector news : Alternative Medicine
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
05/24NOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
05/24SAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Alternative Medicine
Chart BEIJING TONGRENTANG CO., LTD.
Duration : Period :
Beijing Tongrentang Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BEIJING TONGRENTANG CO., L
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 34,1  CNY
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Xiang Guang Liu General Manager & Director
Zhen Kun Gao Chairman
Bao Jian Ma Chairman-Supervisory Board
Hai Ou Gu Director
Zhi Mei Feng Director & Chief Accountant
Sector and Competitors
1st jan.Capitalization (M$)
BEIJING TONGRENTANG CO., LTD.7.27%5 864
CANOPY GROWTH CORP63.07%15 361
AURORA CANNABIS INC65.04%8 371
CRONOS GROUP INC43.74%5 109
DONG-E-E-JIAO CO LTD--.--%3 800
HUTCHISON CHINA MEDITECH LIMITED20.57%3 560